Characterization of impulsivity in Colombian patients with Huntington’s disease
Objective: To describe impulsivity in patients with Huntington's disease using a self-report scale and through an objective test of the inhibition capacity. Describe the demographic…Comorbidities and medications in Huntington’s disease, Parkinson’s disease and the general population in a US claims database
Objective: This study characterises the comorbidities and symptoms, and treatment patterns of patients with Huntington’s disease (HD) vs patients with Parkinson’s disease (PD) vs the…Patient and physician perspectives on the care and assistance needs in Huntington’s disease
Objective: To describe the assistance needs of people with Huntington’s disease (HD) across different countries. Background: HD is a genetic, neurodegenerative and ultimately fatal disease…Ancillary Service Utilization and Impact in Huntington’s Disease
Objective: To determine which Huntington’s disease (HD) patient characteristics correlate with ancillary service utilization. To examine the longitudinal impact of ancillary therapies on clinical characteristics.…High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients
Objective: To assess tolerability and efficacy of high dose Safinamide treatment in Young Onset Parkinson’s Disease (YOPD) patients with dystonia and history of impulse controls…Utilization of Monotherapy and Combination Therapies in Advanced Parkinson Disease Patients During Levodopa-Carbidopa Intestinal Gel Treatment from the COSMOS Study
Objective: Assess the percentages of advanced Parkinson’s disease (APD) patients treated with levodopa-carbidopa intestinal gel (LCIG) as a monotherapy or with add-on PD medications and…Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients, the ability of opicapone (OPC) to act as levodopa-sparing agent. Background: OPC, a once-daily COMT inhibitor,…Amplification of α-synuclein aggregates in cerebrospinal fluid by rapid ultrasonication-based assay
Objective: To apply an ultrasonication-based misfolded protein amplification to the evaluation of α-synuclein aggregates in CSF, and to investigate their clinical significances in Parkinson’s disease…Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)
Objective: To evaluate the clinical effect of istradefylline as adjunctive treatment to LD in PD patients with or without additional PD medications (meds). Background: Istradefylline,…Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson’s disease.
Objective: To evaluate the efficacy of the 5-Hydroxytryptophan (5-HTP) on levodopa-induced motor complications in patients with Parkinson's disease (PD). Background: Several studies have indicated that…
- « Previous Page
- 1
- …
- 152
- 153
- 154
- 155
- 156
- …
- 217
- Next Page »